Guggenheim Sees Upside in Sunrun (RUN); Glaukos (GKOS) Surpasses Forecasts

Sunrun_RUN

Investment analysts at Guggenheim initiated coverage on Sunrun Inc. (Nasdaq:RUN) shares with a Buy rating and a price target of $14.00, representing a more than 84% upside potential over its price at close on Tuesday of $7.59 per share

The residential solar company expects to release its first quarter 2016 financial results on Thursday, May 12, after the closing bell

Sunrun, which engages in the design, development, installation sale, ownership, and maintenance of residential solar energy systems in the U.S., has 101.59M Shares Outstanding, Market Capitalization (intraday) of $771.09M and RUN stock one-year range is from $4.86 to $14.95 per share

*

Glaukos_GKOS

Shares of Glaukos Corp. (NYSE:GKOS) soared more than 20% in the extended session Tuesday after the company delivered quarterly profit and revenue numbers in its financial results that exceeded Wall Street analysts’ expectations.

For the first quarter 2016, Glaukos posted net sales of $23.1 million, a 57% increase year over year, and net income of $897,000, or $0.03 per diluted share, compared to a net loss of ($966,000), or ($0.40) per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of ($0.15) loss per share onrevenues of $18.82 million for the period

The ophthalmic medical technology company has boosted its 2016 net sales guidance to a range of between $100 million and $102 million from the previously reported guidance range of $90 million to $93 million, also exceeding the Capital IQ Consensus Estimate of $91.92 million for the full year

GKOS stock closed at $19.87, up $0.09 (or +0.46%), and 269,351 of its shares exchanged hands during the day

Glaukos, which develops and commercializes products and procedures designed for the treatment of glaucoma, has 32.37M Shares Outstanding, Market Capitalization (intraday) of $643.18M and GKOS stock 52-week range is between $14.25 and $33.92 per share

*

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/